NCT00118170
- Conditions
- Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +83 more
- Locations
-
- Cancer and Leukemia Group B (CALGB) Research Base Chicago, Illinois, United States
Clinical trial condition
Recurrent Marginal Zone Lymphoma
Explore clinical trials studying Recurrent Marginal Zone Lymphoma. Study availability and eligibility vary by location and protocol.
104 public trials
1 recruiting study
Recurrent Marginal Zone Lymphoma trial results
NCT00799461
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, +154 more
- Locations
-
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington, United States
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Megakaryoblastic Leukemia (M7), +136 more
- Locations
-
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
Active, Not Recruiting
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
NCT01479842
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, +29 more
- Locations
-
- Ohio State University Medical Center Columbus, Ohio, United States
Active, Not Recruiting
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
NCT01815749
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Blood Protein Disorders, Burkitt Lymphoma, +64 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
NCT03277729
- Conditions
- Chronic Disease, Disease Attributes, Hematologic Diseases, +43 more
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Active, Not Recruiting
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT01955499
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +21 more
- Locations
-
- University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
Active, Not Recruiting
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
NCT03479268
- Conditions
- B-Cell Prolymphocytic Leukemia, Chronic Disease, Disease Attributes, +40 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
- Roswell Park Comprehensive Cancer Center Buffalo, New York, United States
Active, Not Recruiting
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
NCT01199562
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, +245 more
- Locations
-
- City of Hope Medical Center Duarte, California, United States
Active, Not Recruiting
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
NCT02153580
- Conditions
- B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, Burkitt Lymphoma, +43 more
- Locations
-
- City of Hope Comprehensive Cancer Center Duarte, California, United States